Prenetics Global (NASDAQ:PRE) Downgraded by Wall Street Zen to Sell

Prenetics Global (NASDAQ:PRE – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently commented on the stock. Lucid Cap Mkts raised shares of Prenetics Global to a “strong-buy” rating in a research note on Monday, October 12th. Maxim Group began coverage on shares of Prenetics Global in a research note on Monday, October 26th. They issued a “buy” rating and a $41.00 price target for the company. B. Riley Financial dropped their price target on shares of Prenetics Global from $37.00 to $31.00 and set a “buy” rating for the company in a research note on Thursday. Craig Hallum assumed coverage on shares of Prenetics Global in a report on Thursday, September 17th. They set a “buy” rating and a $40.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $36.17.

Read Our Latest Research Report on PRE

Prenetics Global Stock Down 14.6%

Shares of PRE opened at $8.80 on Friday. Prenetics Global has a 52-week low of $8.69 and a 52-week high of $27.24. The company has a market capitalization of $148.46 million, a PE ratio of -1.73 and a beta of 0.40. The stock has a fifty day simple moving average of $19.24 and a two-hundred day simple moving average of $19.38.

Prenetics Global (NASDAQ:PRE – Get Free Report) last posted its quarterly earnings results on Sunday, November 1st. The company reported ($1.45) EPS for the quarter. The company had revenue of $64.11 million for the quarter. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. As a group, equities analysts anticipate that Prenetics Global will post -2.36 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Danny Sheng Wu Yeung bought 17,181 shares of the stock in a transaction on Monday, August 24th. The stock was bought at an average price of $21.23 per share, with a total value of $364,752.63. Following the completion of the purchase, the chief executive officer directly owned 112,416 shares in the company, valued at $2,386,591.68. This represents a 18.04% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Brian J. Rosin purchased 5,100 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were bought at an average price of $22.80 per share, with a total value of $116,280.00. Following the completion of the transaction, the chief financial officer owned 23,100 shares of the company’s stock, valued at approximately $526,680. The trade was a 28.33% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 40,281 shares of company stock worth $862,453. 7.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Prenetics Global

Large investors have recently made changes to their positions in the stock. State of Wyoming acquired a new position in Prenetics Global during the first quarter worth $48,000. Stevens Capital Partners grew its stake in shares of Prenetics Global by 9.0% in the third quarter. Stevens Capital Partners now owns 30,674 shares of the company’s stock valued at $709,000 after buying an additional 2,527 shares in the last quarter. Operose Advisors LLC acquired a new stake in shares of Prenetics Global in the second quarter valued at $129,000. Virtu Financial LLC purchased a new stake in shares of Prenetics Global in the 3rd quarter valued at $252,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Prenetics Global in the 3rd quarter valued at $253,000. 25.01% of the stock is currently owned by institutional investors and hedge funds.

About Prenetics Global

(Get Free Report)

Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.

Recommended Stories

Analyst Recommendations for Prenetics Global (NASDAQ:PRE)

Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.